• Recordati’s net income climbed 25% to EUR 407.1 million in the first nine months of 2026.
• Net revenue rose 8% to EUR 2.1 billion; Rare Diseases contributed EUR 928.2 million, up 19%.
• Respighi BidCo’s provisional stake reached 91.451%, with a squeeze-out and delisting expected by November’s end, subject to confirmation.
• No interim dividend will be paid for 2026 because of the imminent squeeze-out and delisting.
• The group expects 2026 net revenue near the upper end of its unchanged EUR 2.73 billion–EUR 2.8 billion guidance range.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recordati Industria Chimica e Farmaceutica S.p.A. published the original content used to generate this news brief via SDIR, the Italian regulatory disclosure system (Ref. ID: 216_173509_2026_oneinfo.pdf), on November 10, 2026, and is solely responsible for the information contained therein.